Hengrui Pharmaceutical announced that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for injectable ricaximab from the State Drug Administration and agreed to conduct phase III clinical trials. The indications are for adult patients with intracranial atherosclerotic stenosis to reduce the risk of recurrence of stroke.

Zhitongcaijing · 1d ago
Hengrui Pharmaceutical announced that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for injectable ricaximab from the State Drug Administration and agreed to conduct phase III clinical trials. The indications are for adult patients with intracranial atherosclerotic stenosis to reduce the risk of recurrence of stroke.